Sun Pharma acquires Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio

Sun Pharmaceutical announced that it has acquired three brands viz. Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”). All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.

Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and to get DCGI approval.

Disperzyme and Phlogam, administered orally, offers systemic enzyme-flavonoid therapy. Disperzyme and Phlogam provides the clinicians an evidence-based management solution for inflammation and pain management after minor surgery and dental procedures.

The addition of Disperzyme and Phlogam further strengthens anti-inflammatory portfolio. This systemic enzyme therapy combination controls oedema and it speeds-up the healing process. In a comparative clinical trial in India, these brands provides significantly better control and resolution of post-operative pain and inflammation.